-
公开(公告)号:US09353167B2
公开(公告)日:2016-05-31
申请号:US14478353
申请日:2014-09-05
申请人: MicroVAX, LLC
IPC分类号: A61K39/00 , A61K48/00 , C07K14/47 , C12N15/86 , C07K14/705
CPC分类号: C07K14/4748 , A61K39/0011 , A61K2039/545 , A61K2039/6031 , C07K14/70578 , C12N15/86 , C12N2710/10343
摘要: Provided are methods of generating an immune response to an antigen. The method comprises priming an individual by administering an expression vector encoding the antigen. The vector comprises a transcription unit encoding a secretable fusion protein, the fusion protein containing an antigen and CD40 ligand. Administration of a fusion protein containing the antigen and CD40 ligand is used to enhance the immune response above that obtained by vector administration alone. The methods may be used to generate an immune response against cancer expressing a tumor antigen such as a mucin or human papilloma viral tumor antigen and to generate an immune response against an infectious agent. Also provided is a method for simultaneously producing the expression vector and the fusion protein.
摘要翻译: 提供了产生对抗原的免疫应答的方法。 该方法包括通过施用编码抗原的表达载体来引发个体。 载体包含编码可分泌融合蛋白的转录单元,含有抗原和CD40配体的融合蛋白。 使用含有抗原和CD40配体的融合蛋白的施用用于增强仅通过单独载体给药获得的免疫应答。 该方法可以用于产生针对表达肿瘤抗原例如粘蛋白或人乳头状瘤病毒肿瘤抗原的癌症的免疫应答,并产生针对感染因子的免疫应答。 还提供了同时产生表达载体和融合蛋白的方法。
-
32.
公开(公告)号:US20130149330A1
公开(公告)日:2013-06-13
申请号:US13759224
申请日:2013-02-05
申请人: MicroVAX, LLC
发明人: Albert B. Deisseroth
IPC分类号: A61K39/07
CPC分类号: A61K39/07 , A61K2039/53 , A61K2039/6031 , A61K2039/70 , C07K14/005 , C07K2319/06 , C07K2319/33
摘要: The present invention is directed to novel pharmaceutical compositions and methods of inhibiting or blocking one or more virulence antigenic factors of multiple strains of Bacillus anthracis in an individual. Specifically, it involves the administering of an expression vector alone or in conjunction with a fusion protein. The expression vector has a transcription unit encoding a fusion protein composed of an antigenic factor of Bacillus anthracis or fragment thereof attached via a linker to the aminoterminal end of the CD40 ligand. This fusion protein has the ability to generate antibodies and/or cytotoxic T cells which inhibit or block Bacillus anthracis infection in an individual.
摘要翻译: 本发明涉及新的药物组合物和抑制或阻断个体中多种毒杆菌杆菌的一种或多种毒力抗原因子的方法。 具体地,涉及单独或与融合蛋白结合施用表达载体。 表达载体具有编码融合蛋白的转录单元,该融合蛋白由通过接头连接到炭疽芽孢杆菌的抗原因子或其片段连接到CD40配体的氨基末端。 该融合蛋白具有在个体中产生抑制或阻断炭疽芽孢杆菌感染的抗体和/或细胞毒性T细胞的能力。
-
公开(公告)号:US20130101626A1
公开(公告)日:2013-04-25
申请号:US13662616
申请日:2012-10-29
申请人: MicroVAX, LLC
发明人: Yucheng Tang , Albert Deisseroth
IPC分类号: A61K48/00
CPC分类号: A61K39/0011 , A61K9/127 , A61K48/00 , A61K48/005 , A61K2039/6031 , C07K14/4727 , C07K14/70578 , C07K2319/00 , C12N7/00 , C12N15/85 , C12N15/86 , C12N2710/10043
摘要: Provided are expression vectors for generating an immune response to a mucin. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal, a mucin antigen and CD40 ligand. Also provided are methods of generating an immune response against cells expressing a mucin by administering an effective amount of the vector. Further provided are methods of generating an immune response against cancer cells expressing a mucin in an individual by administering an effective amount of the vector. Still further provided are methods of overcoming anergy to a mucin self antigen by administering an effective amount of the vector.
摘要翻译: 提供了用于产生对粘蛋白的免疫应答的表达载体。 载体包含编码可分泌多肽的转录单位,所述多肽包含分泌信号,粘蛋白抗原和CD40配体。 还提供了通过施用有效量的载体产生针对表达粘蛋白的细胞的免疫应答的方法。 还提供了通过施用有效量的载体来产生针对个体中表达粘蛋白的癌细胞的免疫应答的方法。 还提供了通过施用有效量的载体克服对粘蛋白自身抗原的无反应性的方法。
-
公开(公告)号:US08299229B2
公开(公告)日:2012-10-30
申请号:US10997055
申请日:2004-11-23
申请人: Yucheng Tang , Albert Deisseroth
发明人: Yucheng Tang , Albert Deisseroth
CPC分类号: A61K39/0011 , A61K9/127 , A61K48/00 , A61K48/005 , A61K2039/6031 , C07K14/4727 , C07K14/70578 , C07K2319/00 , C12N7/00 , C12N15/85 , C12N15/86 , C12N2710/10043
摘要: Provided are expression vectors for generating an immune response to a mucin. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal, a mucin antigen and CD40 ligand. Also provided are methods of generating an immune response against cells expressing a mucin by administering an effective amount of the vector. Further provided are methods of generating an immune response against cancer cells expressing a mucin in an individual by administering an effective amount of the vector. Still further provided are methods of overcoming anergy to a mucin self antigen by administering an effective amount of the vector.
摘要翻译: 提供了用于产生对粘蛋白的免疫应答的表达载体。 载体包含编码可分泌多肽的转录单位,所述多肽包含分泌信号,粘蛋白抗原和CD40配体。 还提供了通过施用有效量的载体产生针对表达粘蛋白的细胞的免疫应答的方法。 还提供了通过施用有效量的载体来产生针对个体中表达粘蛋白的癌细胞的免疫应答的方法。 还提供了通过施用有效量的载体克服对粘蛋白自身抗原的无反应性的方法。
-
-
-